



Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer

Upal Basu Roy, PhD, MPH,^{a,*} Anne-Marie Baird, PhD,^b Andrew Ciupek, PhD,^c Jesme Fox, MbChB, MBA,^d Eugene Manley Jr., PhD,^e Kim Norris, XX,^f Giorgio V. Scagliotti, MD, PhD,^g Heather A. Wakelee, MD,^h Tetsuya Mitsudomi, MD,ⁱ Russell C. Clark, JD,^j Renee Arndt, MS,^j Fred R. Hirsch, MD, PhD,^k Paul A. Bunn, MD,^l Matthew P. Smeltzer, PhD^m

^aLUNGeVity Foundation, Bethesda, Maryland

^bLung Cancer Europe and Trinity College, Dublin, Ireland

^cGO2 Foundation for Lung Cancer, Washington, District of Columbia

^dRoy Castle Lung Cancer Foundation, Liverpool, United Kingdom

^eLung Cancer Research Foundation, New York, New York

^fLung Cancer Foundation of America, New Ulm, Minnesota

^gA.O.U. San Luigi Gonzaga Hospital, University of Torino, Orbassano, Italy

^hStanford University, Palo Alto, California

ⁱKindai University Faculty of Medicine, Osaka-Sayama, Japan

^jCancer Technology Applications, LLC, San Diego, California

^kIcahn School of Medicine at Mount Sinai, New York, New York

^lUniversity of Colorado School of Medicine, Aurora, Colorado

^mDivision of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee

Received 1 December 2021; accepted 11 December 2021

Available online 23 December 2021

The past decade of lung cancer research has seen rapid advances in early detection and treatment and many new Food and Drug Administration–approved therapies

for lung cancer. This has largely been possible because of clinical trials. Therapeutic, interventional clinical trials have become a critical component of lung cancer care.

*Corresponding author.

Disclosure: Dr. Roy has received institutional research funding from AstraZeneca, Eli Lilly, Merck, Blueprint Medicine, Genentech, G1 Therapeutics, Takeda, Bristol-Myers Squibb, and Janssen not related to the current project. Dr. Baird has received institutional support funding from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi, and Takeda not related to the project; has served as consultant for Janssen (honorarium received by organization) and for Roche (Dublin, Ireland). Dr. Ciupek has been consultant for Novartis, GRAIL Inc., and advisory board member for Novartis, Daiichi Sankyo, AstraZeneca, and Foundation Medicine. Dr. Fox has received institutional funding from AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Amgen, Novartis, Eli Lilly, Merck, Takeda, and Roche not related to the project and participated in advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Novartis, Debiopharm, and Takeda. Dr. Scagliotti received honoraria from AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, Johnson & Johnson, Takeda; consulting or advisory role for Eli Lilly, BeiGene, and AstraZeneca; received institutional research funding from Eli Lilly and Merck Sharp & Dohme; and received travel, accommodations from Bayer, all not related to the current project. Dr. Mitsudomi received advisory/lecture fees from AstraZeneca, Novartis, Chugai, Boehringer Ingelheim, Pfizer, Roche, Merck Sharp & Dohme, Thermo Fisher, Roche diagnostics, Bristol-Myers Squibb, Ono

Pharmaceutical, Taiho, Takeda, Amgen, Johnson and Johnson, Janssen pharma, Puma, BeiGene, Bridge Biotherapeutics, Eli Lilly, Daiichi Sankyo, and Thermo Fisher; research funding from AstraZeneca, Chugai, Boehringer Ingelheim, Pfizer, Taiho, Ono Pharmaceutical, Merck Sharp & Dohme, Daiichi Sankyo, Eli Lilly, Ethicon, and Bridge Biotherapeutics not related to this project. Dr. Bunn has received consulting income from AstraZeneca, Ascentage, Bristol-Myers Squibb, C-Stone, Imidex, Merck, and Verastem not related to this project. Dr. Smeltzer has worked as a paid research consultant for the Association of Community Cancer Centers. The remaining authors declare no conflict of interest.

Address for correspondence: Upal Basu Roy, PhD, MPH, LUNGeVity Foundation, 6917 Arlington Road, Bethesda, MD 20814. E-mail: ubasuroy@lungevity.org

Cite this article as: Roy UB, Baird AM, Ciupek A, et al. Impact of the coronavirus disease 2019 pandemic on global lung cancer clinical trials: why it matters to people with lung cancer. *JTO Clin Res Rep*. 2021;3:100269.

© 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

ISSN: 2666-3643

<https://doi.org/10.1016/j.jtocrr.2021.100269>

The National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the European Society for Medical Oncology guidelines support clinical trial enrollment as standard of care for people with advanced-stage NSCLC and extensive-stage SCLC in first- and subsequent-line settings. As of September 2021, worldwide, there are approximately 1500 actively recruiting interventional lung cancer trials that would require 405,786 participants.¹ Given that an estimated 2.2 million people were diagnosed with lung cancer globally in 2020,² these recruitment goals may seem attainable. However, owing to various barriers, only 2% to 8% of people with cancer participate in clinical trials.³ This issue has only been exacerbated by the coronavirus disease 2019 (COVID-19) pandemic.

Declared a global pandemic in March 2020, COVID-19 has severely disrupted clinical trial conduct. The International Association for the Study of Lung Cancer commissioned a study to understand the impact of the pandemic on global early detection and therapeutics lung cancer trials and mitigation steps taken by trial sites and sponsors to overcome the impact of the pandemic.⁴ The study reported a 14% decline in patient enrollment between 2019 (prepandemic) and 2020 (postpandemic). Disruptions were more notable in Phase 1 trials, which have numerous monitoring procedures, and those trials which involve infusion of investigational agents requiring frequent travel to study sites. Study sites reported fewer eligible participants, more deviation from protocol compliance, and increased trial suspensions. Regionally, Latin American sites took longer to recover from low recruitment than North American and Western European sites, suggesting that the impact was amplified in regions that already have fewer trials available.

Participants' top concerns included fear of COVID-19 infection, travel restrictions to trial sites, and securing transportation. This led to logistical challenges such as impaired ability to travel to clinical trial sites.

The most effective mitigation strategies reported by sites included flexibility on location requirements (e.g., remote monitoring/diagnostics or using telehealth visits) or timing of procedures (e.g., spacing out visits or assessments) (Fig. 1). Whereas some of these strategies may reduce the burden of trial participation, others may lead to more participant anxiety and increase the impact of disparities among patients in terms of, for example, internet access, device access, or comfort with technology, further impacting trial enrollment.

This study provides an excellent framework to reimagine therapeutic, interventional clinical trial design beyond the pandemic. Approaches should not compromise scientific rigor of trials but should be patient centric, equitable, and minimize burden of participation. As a

team of thoracic oncology leaders and international patient advocates, we provide recommendations (Table 1) for clinical trial stakeholders to consider as the lung cancer community prepares for the postpandemic era.

Role of Clinical Trial Investigators and Sponsors

Clinical trial complexity has increased over the past decade, with trials requiring 59% more trial-related procedures from 2011 to 2015 compared with those from 2001 to 2005.⁵ Almost half of sites surveyed in International Association for the Study of Lung Cancer's study reported a desire to continue utilizing telehealth, remote monitoring (such as the use of routine blood and urine panels), and electronic consent processes. This focus on increased flexibility will allow more people to participate. Indeed, research suggests that structural barriers, such as travel burden, play an outsized role in low trial participation rates relative to other barriers, such as people not being offered trials or refusing participation.⁶ Flexibility in access to trials can help those who are motivated to join but are deterred owing to burdensome logistics. We encourage investigators and sponsors to develop standardized protocols for remote monitoring (allowing clinical, laboratory, and radiology examinations to be performed close to a participant's home, with easy assessment by the central trial site), telehealth visits (providing training to trial staff on the use of telehealth for remote procedures and developing and using validated electronic patient-reported outcome measures for symptom monitoring), electronic consent procedures (training staff, including patient advocates in developing electronic consent procedures), providing flexible options (such as video or telephone conferencing), and remote infusions (when risk is deemed to be low, adverse event monitoring is conducted in real-time, and delivery, storage, and recording usage of experimental drug are streamlined) as mechanisms to foster enrollment and participation.^{7,8} It is important to note that digital technologies such as telehealth come with challenges in reimbursement, medical protection, and legal issues with regard to practice of medicine across state or equivalent boundaries. Until there is clarity on how these challenges will be resolved, continued implementation of telehealth will not be possible in the postpandemic era. Digital technologies can facilitate participation for those who need to travel long distances to study sites. However, they need to be implemented in a manner that permits scalability and national and international applicability and that does not introduce additional inequities in access for patients.

Another important consideration is the incorporation of optional COVID-19 vaccination as part of trial design.⁹




Figure 1. Impact of COVID-19 trial modifications on patient burden of trial participations. Numbers in parentheses indicate the percentages of sites reporting the use of a specific modification. COVID-19, coronavirus disease 2019; IRB, institutional review board.

Such designs will help people understand that they can choose to be vaccinated and participate in a clinical trial at the same time.

Role of Nonpharmaceutical Funders

Lung cancer research is funded by many different private and public sources, varying by country, and the impact of the pandemic on lung cancer research is still being evaluated. The role of nonpharmaceutical funders in drug development was underscored in a recent study that revealed that a substantial fraction of spending by the National Institutes of Health, the largest government funding agency in the United States, is contributing directly or indirectly to new therapies for all diseases, including lung cancer.¹⁰ Governments and industry have focused pandemic-era funding on diagnostics, vaccines, and treatments for COVID-19, leaving research charities

and not-for-profit organizations uncertain of future funding. Half of the Global Lung Cancer Coalition’s members have seen income decreases since the start of the pandemic.¹¹ Large cancer research funders, such as the American Cancer Society, Canadian Cancer Society, and Cancer Research UK have seen large income reductions, leading to reduced research funding.¹² Lung cancer has traditionally been underfunded as a disease, with the National Institutes of Health allocating only 6% of their overall cancer research funding to lung cancer. We urge government funding agencies and private philanthropies to continue to invest in life-saving research that will fuel the drug development pipeline. Lung cancer now leads the solid tumor oncology space with the highest number of treatment options in clinical trials. A decrease in funding will impede progress against this disease.

Table 1. Patient-Centric Recommendations for Conduct of Clinical Trials for Thoracic Oncology Stakeholders

Stakeholders	Recommendations
Clinical trial investigators and sponsors	<ul style="list-style-type: none"> Conduct remote clinical, laboratory, and radiological assessment of on-trial patients as applicable to the phase of the trial Allow for remote infusions (when risk is deemed to be low; distribution, storage, and recording usage of the study drug is possible at local infusion centers; and adverse event monitoring is carried out real-time) or mail-order targeted therapy delivery Develop, train staff, and implement digital protocols for: <ul style="list-style-type: none"> o Patient recruitment, engagement, and retention in clinical trials o ePROs for remote symptom monitoring o Telehealth visits that incorporate video or telephone conferencing—based on individual patient preferences
Regulatory agencies	<ul style="list-style-type: none"> Provide recommendations on how registrational trials provisionally halted during the pandemic should proceed so that registration is not hampered Allow flexibility in patient-centric pandemic regulations (e.g., electronic consent, mail-order medication, and remote monitoring) to proceed in the post-COVID-19 era Provide guidance on how history of or current exposure to SARS-CoV-2 will affect eligibility, trial design, and drug approval and labeling

COVID-19, coronavirus disease 2019; ePRO, electronic patient-reported outcome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Role of Regulatory Agencies

During the early stages of the pandemic, regulatory agencies, such as the U.S. Food and Drug Administration (Silver Spring, MD), the European Medicines Agency, Health Products Regulatory Authority (Dublin, Ireland), and the Healthcare Products Regulatory Agency (London, United Kingdom), rapidly issued guidance on clinical trial conduct. Common themes with direct participant impact revolved around allowing remote monitoring of certain trials through local labs, the impact of COVID-19 status on trial eligibility and participation, mail-order medication delivery, and use of electronic consent procedures. As advocates, we applaud regulators for reacting to the pandemic to ensure that clinical trials continue. It is currently unclear how regulators see these strategies being incorporated into clinical trial design beyond the pandemic. We hope that positive changes made during the pandemic will remain in postpandemic times, given that these changes reduced existing (pre-COVID-19) barriers. Clinical investigators and sponsors will be open to adopting flexible trial designs only if regulators and health technology assessments do not see these designs as impeding registration, drug approval, and reimbursement. Another worry is that changes or a temporary halt to existing trials early in the pandemic will affect the quality or interpretability of trial data and therefore influence future licensing decisions. We encourage regulators to weigh current modifications and issue guidance on how they propose to proceed with regulatory decisions, especially for pivotal clinical trials that are still ongoing. Finally, we request regulators to provide clear guidance on how history of or current exposure to severe acute respiratory syndrome coronavirus 2 will affect eligibility, trial design, and drug approval and labeling.

The COVID-19 pandemic presented an unprecedented global health challenge, the effects of which will continue to be felt for years to come. It also revealed how the global scientific community rapidly pivoted and partnered to develop life-saving vaccines that become available in a time frame that most felt was unattainable. The lung cancer community also rapidly mobilized and formed international consortiums, such as the COVID-19 and Lung Cancer Consortium and TERAVOLT, to understand the impact of the pandemic on the care of patients. This momentum bears testimony to the power of science and collaboration.

Government agencies (such as the National Cancer Institute in the United States) and professional organizations (such as the American Society of Clinical Oncology and the European Society for Medical Oncology) have issued guidance on clinical trial conduct during the pandemic.^{7,8,13} The purpose of this commentary is to

provide the patient advocacy perspective to these recommendations. We acknowledge that incorporating recommendations provided in the framework in this commentary is complex and contingent on several site-specific, policy-specific, and country-specific factors. As advocates, we remain optimistic that the lung cancer clinical trial ecosystem will continue to learn, partner, and innovate—to ensure that clinical trial designs become more patient-centric and that more people continue to have access to life-saving therapies through these trials.

CRedit Authorship Contribution Statement

Upal Basu Roy: Conceptualization.

Upal Basu Roy, Anne-Marie Baird, Andrew Ciupek, Jesme Fox, Eugene Manley, Jr., Kim Norris: Writing - original draft.

Upal Basu Roy, Anne-Marie Baird, Andrew Ciupek, Jesme Fox, Eugene Manley, Jr., Kim Norris, Giorgio V. Scagliotti, Heather A. Wakelee, Tetsuya Mitsudomi, Russell C. Clark, Renee Arndt, Fred R. Hirsch, Paul A. Bunn, Matthew P. Smeltzer: Writing - review & editing.

References

1. ClinicalTrials.gov. Actively recruiting interventional trials in lung cancer. <https://clinicaltrials.gov/>. Accessed January 3, 2022.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71:209-249.
3. Unger JM, Hershman DL, Till C, et al. “When Offered to Participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. *J Natl Cancer Inst.* 2021;113:244-257.
4. Smeltzer M. PL02.09 International Association for the Study of Lung Cancer (IASLC) study of the impacts of COVID-19 on international lung cancer clinical trials. *J Thorac Oncol.* 2021;16(suppl):S847-S848.
5. Getz KA, Campo RA. New benchmarks characterizing growth in protocol design complexity. *Ther Innov Regul Sci.* 2018;52:22-28.
6. Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. *J Natl Cancer Inst.* 2019;111:245-255.
7. Castelo-Branco L, Awada A, Pentheroudakis G, et al. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. *ESMO Open.* 2021;6:100237.
8. Flaherty KT, Doroshow JH, Galbraith S, et al. Rethinking cancer clinical trial conduct induced by COVID-19: an academic center, industry, government, and regulatory agency perspective. *Cancer Discov.* 2021;11:1881-1885.

9. Desai A, Gainor JF, Hegde A, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol*. 2021;18:313-319.
10. Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010-2016. *Proc Natl Acad Sci U S A*. 2018;115:2329-2334.
11. Global Lung Cancer Coalition. Impact of COVID-19: findings from a GLCC members survey. <https://www.lungcancercoalition.org/2020/06/19/impact-of-covid-19-findings-from-a-glcc-members-survey/>. Accessed September 21, 2021
12. Burki TK. Cuts in cancer research funding due to COVID-19. *Lancet Oncol*. 2021;22:e6.
13. Doherty GJ, Goksu M, de Paula BHR. Rethinking cancer clinical trials for COVID-19 and beyond [e-pub ahead of print]. *Nat Cancer*. <https://doi.org/10.1038/s43018-020-0083-x>, accessed January 3, 2022.